Overview
Advances & Controversies in Malignant Hematology & Oncology: Hematology Expert Insights
Hematology Expert Insights
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Advances & Controversies in Malignant Hematology & Oncology is a one-day comprehensive meeting that presents the latest data and cutting-edge updates in the rapidly evolving fields of malignant hematology and oncology. Advances & Controversies is unique in that it addresses questions and controversies emerging from the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO) and other major disease-specific conferences. Faculty from Advances & Controversies were interviewed and asked to engage in a commentary style recording so that individuals who could not participate in the live conference can still benefit from these teachings/learnings. This program compiles those interviews in a viewer-friendly webcast presentation with a focus on malignant hematology.
Program topics include:
Acute Leukemias & Chronic Myelogenous Leukemia
Updates in Chronic Lymphocytic Leukemia
Hodgkin Lymphoma & Indolent Non-Hodgkin Lymphomas
Aggressive Non-Hodgkin Lymphomas
Myeloproliferative Neoplasms
Multiple Myeloma & the Evolving Role of Transplant
Program topics include:
Acute Leukemias & Chronic Myelogenous Leukemia
Updates in Chronic Lymphocytic Leukemia
Hodgkin Lymphoma & Indolent Non-Hodgkin Lymphomas
Aggressive Non-Hodgkin Lymphomas
Myeloproliferative Neoplasms
Multiple Myeloma & the Evolving Role of Transplant
Healthcare providers involved in the care of oncology patients, including medical and surgical oncologists, hematologists, radiation oncologists and diagnostic radiologists, pathologists, oncology fellows and resident trainees, advanced care practitioners, physician assistants, nurses, naturopathic physicians and pharmacists.
Upon participating in this event, individuals will be able to:
• Discuss new data emerging from ASH, ASCO and major disease-specific conferences and implications on the current standards of care*
• Describe how genetic and cellular abnormalities influence disease severity and therapy selection
• Formulate strategies to help mitigate therapy-related adverse events and/or toxicities
• Review how to initiate and individualize therapy
• Utilize current standards of care for patients with cancer
• Discuss new data emerging from ASH, ASCO and major disease-specific conferences and implications on the current standards of care*
• Describe how genetic and cellular abnormalities influence disease severity and therapy selection
• Formulate strategies to help mitigate therapy-related adverse events and/or toxicities
• Review how to initiate and individualize therapy
• Utilize current standards of care for patients with cancer
Pharmacist Learning Objectives: Upon participating in this event, pharmacists will be able to:
• Formulate strategies to help mitigate therapy-related adverse events and/or toxicities
• Review how to initiate and individualize therapy
*This educational program is not an official program of ASH or ASCO, nor is it endorsed by ASH or ASCO.
*This educational program is not an official program of ASH or ASCO, nor is it endorsed by ASH or ASCO.
This activity is sponsored by Cancer Treatment Centers of America (CTCA).
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem while viewing any media (audio/video).
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
5. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
6. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
5. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
6. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Syed A. Abutalib, MD (Program Chair)
Assistant Director
Stem Cell Transplant & Cell Therapy Program
Cancer Treatment Centers of America
Zion, IL
Assistant Director
Stem Cell Transplant & Cell Therapy Program
Cancer Treatment Centers of America
Zion, IL
Jennifer R. Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Ronald Hoffman, MD
Albert A. and Vera G. List Professor of Medicine
Icahn School of Medicine
Director, Myeloproliferative Disorders Research
Program, Tisch Cancer Institute
Mount Sinai Hospital
New York, NY
C. Ola Landgren, MD, PhD
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY
Jerald P. Radich, MD
Professor of Medicine, University of Washington
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA
John W. Sweetenham, MD, FRCP
Professor of Medicine, Department of Hematology
University of Utah
Executive Medical Director and Senior Director of Clinical Affairs
Huntsman Cancer Institute
Salt Lake City, UT
Jane N. Winter, MD
Professor of Medicine, Division of Hematology/Oncology
Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. ACHL also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Clinicians should consult the current manufacturers’ prescribing information for these products.
The following financial relationships have been provided:
Jennifer R. Brown, MD, PhD
Consultant – Celgene, Gilead, Infinity Pharmaceuticals, Janssen, Pharmacyclics/Janssen, Roche/Genentech
Jerald P. Radich, MD
Consulting – BMS, Novartis
John W. Sweetenham, MD, FRCP
Consultant – Sandoz, Seattle GeneticsHonorarium Recipient – Seattle Genetics
Jane N. Winter, MD
Research – Celgene, GSK, Pharmacyclics/Janssen, Medivation, Seattle Genetics
Consultant – Celgene
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
ACHL and CTCA staff members and others involved with the planning, development and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This activity will take approximately 30 minutes to complete. To obtain credit, a score of 60% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, and completed the evaluation. Once the post-test and evaluation are completed, a certificate will be available immediately.
Physicians:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Cancer Treatment Centers of America. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Cancer Treatment Centers of America. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses:
The Academy for Continued Healthcare Learning has been accredited as an Authorized Provider by the International Association for Continuing Education and training (IACET).
The Academy for Continued Healthcare Learning has been accredited as an Authorized Provider by the International Association for Continuing Education and training (IACET).
ACHL is authorized by IACET to offer 0.05 CEU for this program.
IACET CEUs are accepted by the American Nursing Association. Contact your licensing agency for details. 0.05 CEU = 30 minutes
IACET CEUs are accepted by the American Nursing Association. Contact your licensing agency for details. 0.05 CEU = 30 minutes
Pharmacists:
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 0.5 contact hours.
ACPE Universal Activity Number: 0396-9999-16-054-H01-P
Activity Type: Knowledge
Release date: 12/9/16
Expiration date: 12/9/17
Release date: 12/9/16
Expiration date: 12/9/17